2. Signaling Pathways
  3. Metabolic Enzyme/Protease
  4. Factor Xa

Factor Xa

Fxa

Factor Xa

Related Products

PDF 0.5 MB

Factor Xa, a trypsin-like serine protease, is situated at the critical juncture between the intrinsic and extrinsic pathways, catalyzing the conversion of prothrombin to thrombin, and hence plays a pivotal role in the final common pathway of the cascade and has become an important target in the discovery and development of new anticoagulants. Factor Xa is a key protease of the coagulation pathway whose activity is known to be in part modulated by binding to factor Va and sodium ions.

Blood coagulation involves a complex cascade of enzymatic reactions, ultimately generating fibrin, the basis of all blood clots. This cascade is comprised of two arms, the intrinsic and extrinsic pathways which converge at factor Xa to form the common pathway. Factor Xa activates prothrombin to thrombin, which in turn catalyzes the conversion of fibrinogen to fibrin.

Factor Xa Related Products (76):

Cat. No. Product Name Effect Purity Chemical Structure
  • HY-P990060
    Denecimig
    		Inhibitor
    Denecimig (Mim8) is a novel activated coagulation factor VIII-mimetic human bispecific antibody with anti-FIXa and anti-FX arms that potently stimulates FX activation resulting in efficacious haemostasis in vitro and in vivo.
    Denecimig
  • HY-10268B
    Betrixaban hydrochloride
    		Inhibitor
    Betrixaban (PRT054021) hydrochloride is a highly potent, selective, and orally efficacious factor Xa (fXa) inhibitor with an IC50 of 1.5 nM. Betrixaban hydrochloride shows antithrombotic effect.
    Betrixaban hydrochloride
  • HY-128889
    FXIa-IN-1
    		Inhibitor
    FXIa-IN-1 (compound EP-7041) is a potent β-lactam covalent heparin-derived factor XIa (fXIa) inhibitor.
    FXIa-IN-1
  • HY-10264C
    Edoxaban hydrochloride
    		Inhibitor
    Edoxaban (DU-176b) hydrochloride is an orally active, highly potent, selective, and direct Factor Xa (FXa) inhibitor with Ki values of 0.561 and 2.98 nM for free human FXa and prothrombinase. Edoxaban hydrochloride exhibits more than 10,000-fold selectivity over other coagulation proteases. Edoxaban hydrochloride can be used for preventing thromboembolic disease research.
    Edoxaban hydrochloride
  • HY-10268A
    Betrixaban maleate
    		Inhibitor
    Betrixaban (PRT054021) maleate is a highly potent, selective, and orally efficacious factor Xa (fXa) inhibitor with an IC50 of 1.5 nM. Betrixaban maleate shows antithrombotic effect.
    Betrixaban maleate
  • HY-11091
    Razaxaban hydrochloride
    		Inhibitor
    Razaxaban hydrochloride (BMS 561389 hydrochloride) is a highly potent, selective and orally active factor Xa inhibitor with a Ki of 0.19 nM. Razaxaban hydrochloride exhibits excellent selectivity (>5000-fold) for factor Xa over other related serine proteases. Razaxaban hydrochloride is also a potent thrombin inhibitor with a Ki of 540 nM. Razaxaban hydrochloride has strongly antithrombotic activity.
    Razaxaban hydrochloride
  • HY-50903R
    Rivaroxaban (Standard)
    		Inhibitor
    Rivaroxaban (Standard) is the analytical standard of Rivaroxaban. This product is intended for research and analytical applications. Rivaroxaban (BAY 59-7939) is a highly potent, selective and direct Factor Xa (FXa) inhibitor, achieving a strong gain in anti-FXa potency (IC50 0.7 nM; Ki 0.4 nM).
    Rivaroxaban (Standard)
  • HY-10724
    Fidexaban
    		Inhibitor
    Fidexaban is a Factor Xa inhibitor and can be used in research of cardiovascular disease.
    Fidexaban
  • HY-10777
    EMD 495235
    		Inhibitor
    EMD 495235 is a potent and orally active coagulation factor Xa inhibitor with an IC50 of 5.5 nM and a Ki of 6.8 nM. EMD 495235 shows anticoagulant activities.
    EMD 495235
  • HY-105919
    Naroparcil
    		Inhibitor
    Naroparcil is an orally active antithrombotic agent. Naroparcil exhibits antithrombotic effects in rabbit Wessler stasis model with EC50s of 21.9 mg/kg and 36.0 mg/kg after respectively intravenous injection and oral administration.
    Naroparcil
  • HY-145349
    FXIa-IN-6
    		Inhibitor
    FXIa-IN-6 is a potent FXIa inhibitor with selectivity against most of the relevant serine proteases (Ki = 0.3 nM).
    FXIa-IN-6
  • HY-P4576
    Methoxycarbonyl-D-Nle-Gly-Arg-pNA
    Methoxycarbonyl-D-Nle-Gly-Arg-pNA is a synthetic trypsin that can serve as a substrate for coagulation factors IXa (FIXa) and Xa (FXa).
    Methoxycarbonyl-D-Nle-Gly-Arg-pNA
  • HY-11090A
    DPC423
    		Inhibitor
    DPC423 is a highly potent, selective, and orally active factor Xa inhibitor with a Ki of 0.15 nM.
    DPC423
  • HY-P6023
    D-Leu-Pro-Arg-Rh110-D-Pro
    		Chemical
    D-Leu-Pro-Arg-Rh110-D-Pro is a substrate for Factor Xa I (FXIa) with binding affinity. D-Leu-Pro-Arg-Rh110-D-Pro consists of Rhodamine 110 (HY-D0817) linked to a peptide chain through a cleavable bond. Cleavable bond cleavage enhances fluorophore intensity. D-Leu-Pro-Arg-Rh110-D-Pro can be used to detect FXIa activity.
    D-Leu-Pro-Arg-Rh110-D-Pro
  • HY-145354
    FXIa-IN-7
    		Inhibitor
    FXIa-IN-7 is a selective and orally bioavailable factor XIa inhibitor with an IC50 value of 0.4 nM.
    FXIa-IN-7
  • HY-10269
    LY-517717
    		Inhibitor
    LY-517717 is a potent and orally active FXa inhibitor. LY-517717 shows antithrombotic and anticoagulant activity. LY-517717 has the potential for the research of venous thromboembolism after hip or knee replacement.
    LY-517717
  • HY-107966A
    Heparin calcium (MW 3600-5000)
    		Inhibitor
    Heparin (Nadroparin) calcium (MW 3600-5000) is an anticoagulant which binds reversibly to antithrombin III (ATIII) to form a heparin-antithrombin III complex. The complex binds to and irreversibly inactivates thrombin and other activated clotting factors IX, X, XI, and XII and prevents the transformation of fibrinogen to fibrin.
    Heparin calcium (MW 3600-5000)
  • HY-B0597R
    Fondaparinux sodium (Standard)
    		Inhibitor
    Fondaparinux (sodium) (Standard) is the analytical standard of Fondaparinux (sodium). This product is intended for research and analytical applications. Fondaparinux sodium is an antithrombin-dependent factor Xa inhibitor.
    Fondaparinux sodium (Standard)
  • HY-153817
    FXIa-IN-13
    		Inhibitor
    FXIa-IN-13 (example 1) is an Factor Xa inhibitor with antithrombotic activity. FXIa-IN-13 inhibits arteriovenous thrombosis in vivo and in vitro.
    FXIa-IN-13
  • HY-10758
    FXa-IN-1
    		Inhibitor
    FXa-IN-1 is a FXa inhibitor (IC50: 3 nM, Ki: 0.7 nM) with respectable oral bioavailability and half-life in vivo. FXa-IN-1 can be used for thromboembolic disorders.
    FXa-IN-1